Back to Search Start Over

Chronic myelogenous leukemia, version 1.2015.

Authors :
O'Brien S
Radich JP
Abboud CN
Akhtari M
Altman JK
Berman E
Curtin P
DeAngelo DJ
Deininger M
Devine S
Fathi AT
Gotlib J
Jagasia M
Kropf P
Moore JO
Pallera A
Reddy VV
Shah NP
Smith BD
Snyder DS
Wetzler M
Gregory K
Sundar H
Source :
Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2014 Nov; Vol. 12 (11), pp. 1590-610.
Publication Year :
2014

Abstract

Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown to induce favorable response rates in patients with accelerated and blast phase CML. The addition of TKIs to chemotherapy has also been associated with improved outcomes in patients with blast phase CML. Allogeneic hematopoietic stem cell transplant remains a potentially curative option for patients with advanced phase CML, although treatment with a course of TKIs will be beneficial as a bridge to transplant. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with advanced phase CML.<br /> (Copyright © 2014 by the National Comprehensive Cancer Network.)

Details

Language :
English
ISSN :
1540-1413
Volume :
12
Issue :
11
Database :
MEDLINE
Journal :
Journal of the National Comprehensive Cancer Network : JNCCN
Publication Type :
Academic Journal
Accession number :
25361806
Full Text :
https://doi.org/10.6004/jnccn.2014.0159